Stay updated on Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.

Latest updates to the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedDifference0.0%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedAdded site revision: Revision: v3.5.0. Deleted site revision: Revision: v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedAdministrative update: Revision v3.4.2 was added and the previous operating-status notice (rev. 3.4.1) was removed; there is no change to the study content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedNotice about a lapse in government funding and a version update (Revision: v3.4.1) were added, while Revision: v3.4.0 was removed; no substantive study content changes are indicated. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedGlossary information is now shown on the page. The footer metadata has been updated to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and a revision note 'v3.4.0' (replacing v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.